Status:
COMPLETED
Effects of Alpha Lipoic Acid Supplementation on Metabolic Syndrome Markers in Young Overweight or Obese Males
Lead Sponsor:
University of La Verne
Conditions:
Metabolic Syndrome
Obesity
Eligibility:
MALE
18-35 years
Phase:
NA
Brief Summary
Eight weeks supplementation of alpha lipoic acid (known superantioxidant already produced by the body) will significantly improve metabolic syndrome markers (e.g., excess body weight, blood pressure, ...
Detailed Description
Young adults exhibit an increasing prevalence of obesity, pre-diabetes, and metabolic syndrome that contribute to increased risk of type II diabetes and cardiovascular heart disease later in life. Twe...
Eligibility Criteria
Inclusion
- Overweight or obese (body mass index 25 - 35 kg/m2)
- Males (18-35 years)
- Able to ingest supplement or placebo
Exclusion
- Female (due to menstrual cycle fluctuations)
- Unable to read English at the time of consent
- Have a body mass index under 25 kg/m2 or over 35 kg/m2
- Diabetes
- Impaired glucose tolerance (fasting plasma glucose levels \>110 mg/dL
- Hypertension (SBP\>130mmHg or DBP\>90mmHg)
- Cardiovascular problems or disease
- Psychiatric problems
- History of alcohol abuse (intake of \>500 g/wk in the last year)
- Current or recent (in the past 3 years) smoking
- Certain medication or dietary supplement use (medications or dietary supplements known to cause weight loss/gain or metabolic improvements/dysfunction. Paxil or (paroxetine), Prozac (fluoxetine), Remeron (mirtazapine), Zyprexa (olanzapine), Deltasone (prednisone), Thorazine (chlorpromazine), Elavil, Endep, Vanatrip (amitriptyline), Depakote (valproic acid), Allegra (fexofenadine and pseudoephedrine), Diabinese or Insulase
- Symptoms of chronic or current infection
- A chronic inflammatory condition
- Any thyroid condition, and/or liver disease or malignancy
Key Trial Info
Start Date :
October 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT03342599
Start Date
October 1 2013
End Date
September 1 2016
Last Update
November 17 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of La Verne Kinesiology Laboratory
La Verne, California, United States, 91750